Stockscreener 앱 받기
31.63
1.31%
0.41
전일 마감가:
$31.22
열려 있는:
$31.38
하루 거래량:
2.41M
Relative Volume:
1.05
시가총액:
$5.22B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
16.22
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
+6.64%
1개월 성능:
+12.72%
6개월 성능:
+8.32%
1년 성능:
+6.32%
1일 변동 폭
$31.15
$31.87
1주일 범위
$28.93
$31.96
52주 변동 폭
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
31.63 | 5.15B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-11 | 개시 | Truist | Buy |
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Aug Final Week: Is Alkermes plc benefiting from interest rate changesJobs Report & Short-Term High Return Ideas - baoquankhu1.vn
Recap Report: Can Alkermes plc stock outperform in a bear market - baoquankhu1.vn
Erasca Stock Surges 42% in a Week: Here's What You Should Know - Finviz
ALKS: RBC Capital Raises Price Target to $47, Maintains 'Outperf - GuruFocus
Piper Sandler Raises Price Target for ALKS to $45, Reiterates Ov - GuruFocus
Are Medical Stocks Lagging Alkermes (ALKS) This Year? - sharewise.com
Avadel Pharmaceuticals shareholders approve $2.37B takeover bid - The Business Journals
Apellis Stock Crashes 23% in a Week: Here's What You Should Know - Finviz
Alkermes PLC (ALKS) Stock Price Up 3.16% on Jan 15 - GuruFocus
Alkermes (NASDAQ:ALKS) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? - Finviz
Best Value Stocks to Buy for Jan.14 - The Globe and Mail
Update Report: Can inTEST Corporation scale operations efficientlySell Signal & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Improved Earnings Required Before Alkermes Plc (NASDAQ:ALKS) Shares Find Their Feet - 富途牛牛
Aug Rallies: Will Alkermes plc stock remain a Wall Street favorite2025 Volume Leaders & Momentum Based Trading Ideas - Bộ Nội Vụ
Retail Trends: Can Alkermes plc stock deliver 10 annual returnsInsider Selling & Precise Trade Entry Recommendations - Bộ Nội Vụ
Avadel Shareholders Approve Acquisition by Alkermes - Sleep Review
Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close - Yahoo Finance
ALKS: ALKS 2680 advances to Phase 3, targeting major sleep disorders and expanding commercial reach - TradingView — Track All Markets
ALKS: ALKS 2680 advances as a potential blockbuster, driving growth and sleep medicine expansion - TradingView — Track All Markets
Avadel shareholders approve acquisition by Alkermes - Investing.com Nigeria
Alkermes (ALKS) Secures Shareholder Approval for Avadel Acquisition - GuruFocus
Avadel Shareholders Approve Acquisition by Alkermes plc - TipRanks
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes - The Manila Times
Avadel Pharmaceuticals plc Approves Scheme of Arrangement for Alkermes Acquisition - Quiver Quantitative
Shareholders back Avadel sale to Alkermes after strong vote - Stock Titan
Alkermes plans Avadel acquisition to expand sleep portfolio - TipRanks
Alkermes plc (ALKS): Investor Outlook Reveals 47.29% Potential Upside Amid Robust Product Pipeline - DirectorsTalk Interviews
How to contact the Daily Bulletin - FinancialContent
Buybacks Report: What dividend safety score for Alkermes plc stock2025 Key Highlights & Smart Swing Trading Techniques - Bộ Nội Vụ
Is Alkermes plc (8AK) stock a momentum leaderJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - Улправда
Is Alkermes plc stock positioned for digital transformation2025 Growth vs Value & Capital Protection Trade Alerts - Улправда
What dividend safety score for Alkermes plc stockMarket Sentiment Review & High Yield Equity Trading Tips - Улправда
Technical Reactions to ALKS Trends in Macro Strategies - Stock Traders Daily
Workboat Indexes - FinancialContent
Top Biotech Players REGN, INCY, PTCT Among Participants At J.P.Morgan Healthcare Conference 2026 - RTTNews
How FDA Breakthrough Therapy Status for Alixorexton Will Impact Alkermes (ALKS) Investors - Sahm
Will Alkermes plc stock split attract more investorsJuly 2025 Opening Moves & Free Technical Confirmation Trade Alerts - Улправда
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge - MSN
Alkermes: Avadel Deal And Vibrance-2 Unlock Upside - Seeking Alpha
Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 5,000 Shares - MarketBeat
Alkermes plcOrdinary Shares (NQ: ALKS - FinancialContent
Is Alkermes plc stock supported by innovation pipelineGold Moves & Free Accurate Trade Setup Notifications - ulpravda.ru
Is Alkermes plc stock a good choice for value investors2025 Trading Volume Trends & Free Technical Confirmation Trade Alerts - ulpravda.ru
FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug - Finviz
Alkermes plc's (NASDAQ:ALKS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? - simplywall.st
Why Analysts See The Alkermes (ALKS) Story Shifting After Avadel Deal And Orexin Data - Yahoo Finance
FDA Grants Alixorexton Breakthrough Therapy Designation for Narcolepsy Type 1 - Sleep Review
Is Alkermes plc (8AK) stock a top pick for value investorsTrade Performance Summary & Weekly Breakout Opportunity Watchlist - ulpravda.ru
Is Alkermes (ALKS) Pricing Reflect Its DCF Value Gap And Recent Mixed Returns - Yahoo Finance UK
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition - MSN
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alkermes Plc 주식 (ALKS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Jan 08 '26 |
Option Exercise |
19.34 |
5,000 |
96,700 |
66,740 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Jan 08 '26 |
Sale |
30.00 |
5,000 |
150,005 |
61,740 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer |
Jan 02 '26 |
Sale |
28.00 |
4,000 |
112,000 |
61,740 |
1.30%
1.45%
자본화:
|
볼륨(24시간):